You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
美股異動 | 再生元製藥盤中漲17% 治療糖尿病黃斑水腫和濕性年齡相關性黃斑變性關鍵試驗達到主要終點
格隆匯 09-08 22:30
格隆匯9月8日丨再生元製藥(REGN.US)盤中漲17.36%,報700美元,總市值763億美元,刷新4月22日以來盤中高位。消息面上,兩份試驗結果表明,該公司aflibercept治療(眼科)濕性年齡相關性黃斑變性(AMD)的概念驗證2期臨牀試驗達到主要終點。Aflibercept 8mg是由再生元製藥和Bayer AG(BAYRY.US)聯合開發的。在美國,Regeneron擁有Eylea和aflibercept 8 mg的專有權,拜耳獲得了Eylea在美國以外地區的獨家營銷權,兩家公司平分Eylea銷售的利潤。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account